1 high-potential cannabis stock I like

Unlike other listed cannabis companies, this one is revenue-making and even has a visible pipeline. Manika Premsingh thinks its future looks bright.  

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

MGC Pharmaceuticals (LSE: MXC) was the first cannabis company to list on the London Stock Exchange earlier this year. While the stock saw a good opening, its share price has fallen to less than half its initial highs. 

There is little to pin the share price fall on, though. All listed cannabis stocks have seen a reversal in stock market fortunes in the past few months. As far as I can tell, regulation has not changed for the worse. 

So, if anything, I think this could be an opportunity to buy stocks in the cannabis industry, which is slated to grow fast.

Robust revenue growth

Among the cannabis stocks listed on the London Stock Exchange, that include the David Beckham-backed Cellular Goods and the medical and wellness solutions provider Kanabo Group, I think MGC Pharma has an advantage. 

It has been around far longer than any of the others. And it has a revenue stream. Cellular Goods is pre-revenue and Kanabo has some revenues from its pilots, but that is about all. 

MGC Pharma, on the other hand, has been generating revenue for years now. For the financial year ending June 30 2020, its revenues were at A$2m, which was more than three times the levels seen in the year before. 

Its latest trading update released last month was encouraging too. It says that in March it saw its “best monthly sales revenue”, and for the quarter ending March 2021, it had a “record quarter of sales revenues from its proprietary phytomedicine product line”

Visible pipeline

The company, which produces cannabis-based medicines, saw this increase in sales as it delivered a bulk order to SwissPharmaCan, a nutraceutical company. Nutraceuticals refer to any food with health benefits beyond nutrition.

This sale alone almost doubled MGC Pharma’s revenue for the quarter. Specifically, it supplied an anti-inflammatory supplement, which is aimed at countries with a high incidence of Covid-19. 

Further, it now has a three-year contract with SwissPharmaCan, which guarantees revenues for the company. I think this bodes well for its share price. 

Contextualising the losses

MGC Pharma is still loss-making, but I do not think that needs to get in the way of its share price performance. There are multiple examples of high-performing stocks in growing industries that are also loss making. 

Consider FTSE 100 stocks like Ocado or Just Eat Takeaway. They are expanding fast, as is evident from their double-digit growth rates. Both companies have given a new spin to an old business, by digitising grocery and restaurant deliveries respectively. And both are running with losses. 

I see MGC Pharma in the same light. Here, though, the one big risk is that regulation may turn against cannabis companies, if any serious side effects to their products are discovered.

My takeaway

Otherwise though, if MGC Pharma continues to increase its revenues, I think its stock can do quite well. I am watching it closely. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh owns shares of Ocado Group. The Motley Fool UK has recommended Just Eat Takeaway.com N.V. and Ocado Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »